These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31057354)

  • 21. The Cerebellar Dopaminergic System.
    Flace P; Livrea P; Basile GA; Galletta D; Bizzoca A; Gennarini G; Bertino S; Branca JJV; Gulisano M; Bianconi S; Bramanti A; Anastasi G
    Front Syst Neurosci; 2021; 15():650614. PubMed ID: 34421548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.
    Gragnoli C; Reeves GM; Reazer J; Postolache TT
    Transl Psychiatry; 2016 Apr; 6(4):e785. PubMed ID: 27093067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
    Reynolds GP; Templeman LA; Zhang ZJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy.
    Swathy B; Banerjee M
    Epigenomics; 2017 May; 9(5):721-736. PubMed ID: 28470099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive impairment on motor imagery associated with positive symptoms in patients with first-episode schizophrenia: evidence from event-related brain potentials.
    Chen J; Wei D; Yang L; Wu X; Ma W; Fu Q; Wang H; Liu G; Deng Z; Ye M; Zhang Y; Zhang Z
    Psychiatry Res; 2015 Mar; 231(3):236-43. PubMed ID: 25612462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How can genetics help understand the relationship between cognitive dysfunction and schizophrenia?
    Smeland OB; Andreassen OA
    Scand J Psychol; 2018 Feb; 59(1):26-31. PubMed ID: 29356008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia.
    Turčin A; Dolžan V; Porcelli S; Serretti A; Plesničar BK
    OMICS; 2016 May; 20(5):283-9. PubMed ID: 27195966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial Dysfunction in Schizophrenia.
    Ni P; Chung S
    Bioessays; 2020 Jun; 42(6):e1900202. PubMed ID: 32338416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacogenetics and tailored drug treatment in schizophrenia].
    Andreassen OA; Steen VM
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Voltage-gated calcium channel activity and complex related genes and schizophrenia: A systematic investigation based on Han Chinese population.
    Zhang T; Zhu L; Ni T; Liu D; Chen G; Yan Z; Lin H; Guan F; Rice JP
    J Psychiatr Res; 2018 Nov; 106():99-105. PubMed ID: 30308413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia.
    Amato D; Kruyer A; Samaha AN; Heinz A
    Front Psychiatry; 2019; 10():314. PubMed ID: 31214054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic association between 5'-upstream single-nucleotide polymorphisms of PDGFRB and schizophrenia in a Korean population.
    Kim HJ; Kim MH; Choe BK; Kim JW; Park JK; Cho AR; Bae H; Shin DH; Yim SV; Kwack K; Kwon YK; Chung JH
    Schizophr Res; 2008 Aug; 103(1-3):201-8. PubMed ID: 18541413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.
    Greenbaum L; Strous RD; Kanyas K; Merbl Y; Horowitz A; Karni O; Katz E; Kotler M; Olender T; Deshpande SN; Lancet D; Ben-Asher E; Lerer B
    Pharmacogenet Genomics; 2007 Jul; 17(7):519-28. PubMed ID: 17558307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacogenetics of antipsychotic-induced adverse events.
    Müller DJ; Chowdhury NI; Zai CC
    Curr Opin Psychiatry; 2013 Mar; 26(2):144-50. PubMed ID: 23370274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.
    Porcelli S; Balzarro B; Lee SJ; Han C; Patkar AA; Pae CU; Serretti A
    Neuropsychobiology; 2016; 73(3):160-8. PubMed ID: 27092952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NURR1 and ERR1 Modulate the Expression of Genes of a
    Torretta S; Rampino A; Basso M; Pergola G; Di Carlo P; Shin JH; Kleinman JE; Hyde TM; Weinberger DR; Masellis R; Blasi G; Pennuto M; Bertolino A
    J Neurosci; 2020 Jan; 40(4):932-941. PubMed ID: 31811028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.
    Liu SK; Fitzgerald PB; Daigle M; Chen R; Daskalakis ZJ
    Biol Psychiatry; 2009 Mar; 65(6):503-9. PubMed ID: 18950746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of spine homeostasis causes dopaminergic compensatory up-regulation, resulting in schizophrenia.
    Sato K
    Med Hypotheses; 2012 Sep; 79(3):304-7. PubMed ID: 22683237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia.
    Porcelli S; Pae CU; Han C; Lee SJ; Patkar AA; Masand PS; Balzarro B; Alberti S; De Ronchi D; Serretti A
    Int J Mol Sci; 2015 Jan; 16(2):2517-29. PubMed ID: 25622261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.